We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-4.24%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$4.4B
AUM Growth
-$1.33B
Cap. Flow
-$405M
Cap. Flow %
-9.2%
Top 10 Hldgs %
53.32%
Holding
82
New
7
Increased
5
Reduced
49
Closed
11
Avg Time Held
1.8 years
Top 10 Avg Time Held
1.7 years
Top 20 Avg Time Held
1.2 years

Top Buys

Rank Stock Value
1
SNCE
Science 37 Holdings, Inc. Common Stock
SNCE
+$220M
2
AUGX icon
Augmedix, Inc. Common Stock
AUGX
+$52.1M
3
TRDA icon
Entrada Therapeutics
TRDA
+$47.4M
4
CNC icon
Centene
CNC
+$26.5M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$24.6M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$100M
2
ARGX icon
argenx
ARGX
+$63.6M
3
DCPH icon
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$63.3M
4
SKIN icon
SkinHealth Systems
SKIN
+$61.9M
5
CLDX icon
Celldex Therapeutics
CLDX
+$38.3M

Sector Composition

Rank Sector Weight
1 Healthcare 96.18%
2 Consumer Staples 2.79%
3 Industrials 1.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ICUI icon
26
ICU Medical
ICUI
$4.18B
$52.2M 1.19%
219,926
-2,600
-1% -$607K
2020 Q2
6 quarters
ELV icon
27
Elevance Health
ELV
$92.9B
$51.1M 1.16%
110,289
-17,213
-14% -$7.24M
2020 Q4
4 quarters
SLGC
28
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$48.2M 1.1%
4,142,770
+170,500
+4% +$2.04M
2021 Q3
1 quarter
STTK icon
29
Shattuck Labs
STTK
$555M
$47.8M 1.09%
5,619,914
– –
2020 Q4
4 quarters
AUGX icon
30
DELISTED
Augmedix, Inc. Common Stock
AUGX
$45.3M 1.03%
+14,380,327
New +$52.1M
2021 Q4
0 quarters
GRTS icon
31
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$44.1M 1%
3,429,171
+608,086
+22% +$6.73M
2018 Q3
13 quarters
PLRX icon
32
Pliant Therapeutics
PLRX
$60.2M
$41.6M 0.95%
3,083,501
– –
2020 Q2
6 quarters
OSH
33
DELISTED
Oak Street Health, Inc.
OSH
$39.9M 0.91%
1,203,619
-674,901
-36% -$25.5M
2020 Q3
5 quarters
PRTA icon
34
Prothena Corp
PRTA
$436M
$37.8M 0.86%
765,675
-135,816
-15% -$7.53M
2021 Q1
3 quarters
ANNX icon
35
Annexon
ANNX
$682M
$37.1M 0.84%
3,228,917
-120,268
-4% -$1.94M
2020 Q3
5 quarters
AKRO icon
36
DELISTED
Akero Therapeutics
AKRO
$33.9M 0.77%
1,602,285
-1,085,159
-40% -$24.1M
2019 Q2
10 quarters
TRDA icon
37
Entrada Therapeutics
TRDA
$186M
$33.5M 0.76%
+1,954,420
New +$47.4M
2021 Q4
0 quarters
NUVB icon
38
Nuvation Bio
NUVB
$1.67B
$31.2M 0.71%
3,671,009
-870,000
-19% -$8M
2021 Q1
3 quarters
CNC icon
39
Centene
CNC
$34.8B
$29.8M 0.68%
+361,139
New +$26.5M
2021 Q4
0 quarters
STVN icon
40
Stevanato
STVN
$5.26B
$26.3M 0.6%
1,170,225
-16,800
-1% -$399K
2021 Q3
1 quarter
GMAB icon
41
Genmab
GMAB
$23.3B
$26.2M 0.6%
661,621
-458,767
-41% -$19.1M
2021 Q1
3 quarters
ISEE
42
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$25.1M 0.57%
+1,500,000
New +$24.6M
2021 Q4
0 quarters
STLN icon
43
Starling Oncology
STLN
$704M
$24.4M 0.55%
+2,500,000
New +$22.2M
2021 Q4
0 quarters
IMTX icon
44
Immatics
IMTX
$1.09B
$23.7M 0.54%
1,765,692
-176,200
-9% -$2.2M
2020 Q3
5 quarters
NVRO icon
45
DELISTED
NEVRO CORP.
NVRO
$21.9M 0.5%
270,116
-272,816
-50% -$27.3M
2019 Q1
11 quarters
ALLK icon
46
DELISTED
Allakos
ALLK
$20.3M 0.46%
2,077,875
-53,921
-3% -$4.42M
2018 Q3
13 quarters
BVS icon
47
Bioventus
BVS
$943M
$19.2M 0.44%
1,325,139
-164,717
-11% -$2.34M
2021 Q1
3 quarters
NGNE icon
48
Neurogene
NGNE
$479M
$16.8M 0.38%
174,542
-820
-0.5% -$99.9K
2019 Q4
8 quarters
ALXO icon
49
ALX Oncology
ALXO
$138M
$16.8M 0.38%
782,097
-82,338
-10% -$3.55M
2020 Q3
5 quarters
ZGNX
50
DELISTED
Zogenix, Inc.
ZGNX
$16.2M 0.37%
998,114
-16,300
-2% -$239K
2021 Q3
1 quarter
1
2
3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2021 Portfolio in Review

As of Q4 2021, Redmile Group held 82 positions worth $4.4B, down 23% from $5.73B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Redmile Group withdrew a net $405M in Q4 2021, closing 11 positions and reducing 49 holdings. Its most notable exit was Amedisys, an estimated $22.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Redmile Group opened a new position in Science 37 Holdings, Inc. Common Stock worth $247M.

  • Redmile Group's largest Q4 2021 buy was Science 37 Holdings, Inc. Common Stock: 990,412 shares worth $247M.
  • Redmile Group added most to Amicus Therapeutics in Q4 2021, an estimated $21.4M increase.
  • Redmile Group's biggest Q4 2021 reduction was Jazz Pharmaceuticals, cutting an estimated $100M.
  • Redmile Group fully exited Amedisys in Q4 2021, selling an estimated $22.4M.
  • Redmile Group's ten largest holdings make up 53% of its $4.4B portfolio in Q4 2021.
  • Redmile Group opened 7 new positions and closed 11 in Q4 2021.
  • Redmile Group's portfolio value fell 23% quarter-over-quarter to $4.4B.

Based on Redmile Group's 13F filing for Q4 2021, filed 14 Feb 2022.